

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

NCT07253688

Status	RECRUITING
Phase	Phase 3
Sponsor	Todd C. Lee MD MPH FIDSA
Enrollment	330 participants

Key Eligibility Criteria

Inclusion (2)

- Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);
- Patient or healthcare proxy provide informed consent.

Exclusion (14)

- Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis < 90 days according to the treating team;
- Patient requires intensive care but has a do not resuscitate order precluding transfer;
- Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);
- Organism tests as rifampin resistant;
- History of hypersensitivity/anaphylaxis or severe adverse reaction to rifampin;
- ... and 9 more (see full listing online)

Locations (1 total)

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada